Mobile

A PHASE Ib/II, OPEN LABEL, MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF Apo2L/TRAIL ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR AND OTHER...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005552-33

A PHASE Ib/II, OPEN LABEL, MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF Apo2L/TRAIL ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR AND OTHER LOW-GRADE, CD20, B CELL NON HODGKIN’S LYMPHOMAS THAT HAVE PROGRESSED FOLLOWING PREVIOUS RITUXIMAB THERAPY

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

phase II: to evaluate the safety of multiple doses of Apo2L/TRAIL administered in combination with rituximab to subjects with relapsed follicular NHL who have progressed following stable disease or an objective response to a previous rituximab-containing regimen, and to evaluate the efficacy of multiple doses of Apo2L/TRAIL administered in combination with rituximab to subjects with relapsed follicular NHL, as measured by response rate.

Critère d'inclusion

  • phase II: patients with follicular NHL

Liens